NASDAQ: ABVC

ABVC BIOPHARMA

Corporate Overview

SPRING 2022

Company Overview

ABVC BioPharma licenses promising medical research conducted in the Asia-Pacific region and enlists top-ranked principal investigators in the United States to conduct Phase I and Phase II clinical trials. We specialize in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes that represent significant commercial potential.





NASDAQ: ABVC

Business Model

ABVC BioPharma develops its pipeline by carefully tracking new medical discoveries and medical device technologies from research institutions in the Asia-Pacific region.

We closely examine pre-clinical and animal model studies to identify solutions that ABVC believes demonstrate efficacy and safety based on our rigorous standards.

Once a potential drug or medical device is shown to be a good candidate for further development and ultimate commercialization, we license it from the original researchers and introduce our clinical plan to highly respected principal investigators in the United States, Australia, and Taiwan.

Upon successful completion of Phase II clinical studies, ABVC accesses global markets through out-licensing to international pharmaceutical companies.

NASDAQ: ABVC

SPRING 2022

Botanicals Specialization

Over the past decades, herbal medicines from Asia typically exhibit fewer adverse side effects than those derived from animals or synthetic ingredients.

Many herbal drugs developed in the West have also been successful in addressing some of our most intractable diseases.

- Bayer introduced Aspirin from a compound found in the bark and leaves of willow trees and,
- Eli Lilly used anticancer compounds found in rosy periwinkle to produce effective treatments for leukemia and Hodgkin's disease.

With one foot in Asia and the other in the United States, ABVC plays a unique role by bringing some of the most powerful active herbal ingredients to the world by undergoing rigorous US FDA clinical trials that lead to global distribution of safe and effective medicines.



NASDAQ: ABVC

Near-term Drug Pipeline

SPRING 2022

MEDICAL CONDITION	ABVC DRUG	PIPELINE STATUS	CLINICAL PARTNER	GLOBAL MARKET SIZE
Major Depressive Disorder (MDD)	ABV-1504	Phase II Completed	Stanford University Medical Center, Taipei Veterans General Hospital	$13.7 Billion (2018)[1]
Adult Attention Deficit Hyperactivity Disorder (ADHD)	ABV-1505	Phase II Part 1 Completed	University of California San Francisco (UCSF), School of Medicine	$16.4 Billion (2018)[2]
Myelodysplastic Syndrome (MDS)	ABV-1702	Phase II	TBD	$1.8 Billion (2018)[3]
Advanced Inoperable or Metastatic Pancreatic Cancer	ABV-1703	Phase II	TBD	$1.8 Billion (2018)[4]

1. https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Global-and-Southeast-Asia-Major-Depressive-Disorder-Drug-Market/Summary
2. https://www.grandviewresearch.com/industry-analysis/attention-deficit-hyperactivity-disorder-adhd-market
3. https://www.grandviewresearch.com/industry-analysis/myelodysplastic-syndrome-mds-drugs-market
4. https://www.businesswire.com/news/home/20180921005224/en/4.05-Bn-Pancreatic-Cancer-Therapy-Market-to-2025

Clinical Trial Principal Investigators

Stanford University

- Major Depressive Disorder (MDD)

UCSF

- Attention Deficit Hyperactivity Disorder (ADHD)

Memorial Sloan Kettering Cancer Center

- Myelodysplastic Syndrome (MDS)

Henry Ford Health System

- Solid Tumors

Cedars-Sinai

- Depression in Cancer Patients
- Triple Negative Breast Cancer
- Pancreatic Cancer

Sydney Hospital & Sydney Eye Hospital

- Vitargus®

MEDICAL DEVICES

Vitargus® ABV-1701

- Vitreous, gel-like substance that helps the eye maintain a round shape and keeps the retina in place during and after retinal re-attachment surgery.
- Current vitreous substitutes (air, silicone oil, octafluoropropane, sulfur hexafluoride) have disadvantages that often lead to medical complications and additional surgeries.
- After retinal re-attachment utilizing Vitargus®, the patient does not require face-down positioning and has an immediate improvement in visual acuity.



MEDICAL DEVICES

Vitargus® ABV-1701

First-In-Human clinical trials conducted at the Sydney Eye Hospital in Australia have demonstrated that Vitargus:

- Provides an immediate improvement in visual acuity after surgery.
- Permits a patient to have unrestricted post-surgery movement or activity.
- Requires no post-op fluid removal since it is derived from natural ingredients and is completely biodegradable.

A Phase II clinical trial will be started in early 2022 and global out-licensing agreements in Australia, Thailand, Taiwan, Mainland China, and India are expected before the end of 2023.

More than 1.9 million patients worldwide underwent vitrectomy surgery in 2019. The global retinal surgery device market is expected to exceed $3.0 bn by 2025.

CENTRAL NERVOUS SYSTEM

NASDAQ: ABVC **SPRING 2022**

ABV-1504 Major Depressive Disorder (MDD)
ABV-1505 Attention Deficit Hyperactivity Disorder (ADHD)
ABV-1601 Depression in Cancer Patients

ABV-1504: successfully completed Phase I and Phase II clinical studies for treating MDD.

ABV-1505: successfully completed Phase II Part 1 clinical study for treating ADHD.
Phase II Part 2 clinical study expected to be completed by the end of 2022.

ABV-1601: Phase I clinical study for treating MDD in cancer completed by end of 2022.

- PDC-1421, the active ingredient in ABV-1504, ABV-1505 and ABV-1601 is extracted from the dry root of *Polygala tenuifolia* (yuan zhi).
- PDC-1421 contains only 1.4% (w/w) of this raw material and is formulated as a capsule form for oral administration.
- Clinical trials to date involving PDC-1421 have demonstrated significant patient improvement over Prozac with with no major side effects of suicidal ideation, sexual dysfunction or emotional blunting.
- Global patents have been granted in the US, EU, and several Asian countries.

ONCOLOGY

NASDAQ: ABVC **SPRING 2022**

ABV-1501 Triple Negative Breast Cancer (TNBC)
ABV-1703 Pancreatic Cancer
ABV-1702 Myelodysplastic Syndrome (MDS)

1501, 1702 and 1703 have received US FDA IND Approval and are in a Phase II clinical study.

- Active ingredient, BLEX-404, derived from the Maitake mushroom.
- Phase I/II BLEX 404 dose escalation trial[1] performed at Memorial Sloan Kettering Cancer Center (MSKCC) with 34 postmenopausal breast cancer patients demonstrated BLEX 404 patients were:

  ✓ Free of disease after initial treatment, were enrolled sequentially in five cohorts: 0.1, 0.5, 1.5, 3, or 5 mg/kg BID for 3 weeks and,

  ✓ No dose-limiting toxicity was observed and,

  ✓ Both immunologically stimulatory and inhibitory measurable effects in collected peripheral blood from patients.

- Another Phase II trial[2] at MSKCC demonstrated the effects of Maitake BLEX 404 on innate immune function in 21 myelodysplastic syndromes (MDS) patients.

1. Cancer Immunol Immunotherapy (2015) 64:237–247
2. Cancer Res Clin Oncol (2009) 135:1215–1221

NASDAQ: ABVC

Management Team

Howard Doong, M.D., Ph. D. Chief Executive Officer

Formerly CAP-certified Laboratory Director of Taipei Veteran General Hospital Laboratory of Cancer Genomic Medicine, CEO of Frasergen Genomic Medicine Corp. and Vice President of TrimGen Corporation, a manufacturer of molecular diagnostic reagents and medical instruments. Formerly professor at the University of Maryland and researcher at National Institutes of Health (NIH). Ph.D., University of Chicago, Department of Organismal Biology and Anatomy and Department of Surgery. MD/Ph.D., Harvard-MIT Division of Health Sciences and Technology.



Dr. T.S. Jiang Chief Strategy Officer and Director

Formerly, President of PhytoHealth Corporation, led the team that developed and commercialized PG2 Lyo Injection, a drug to treat cancer related fatigue. Previously director of the Taiwan Bio Industry Organization, Taiwan's leading industry association representing the entire life sciences industry spectrum.



NASDAQ: ABVC

Management Team

SPRING 2022



Dr. Chi-Hsin Richard King Chief Scientific Officer

Formerly Senior Vice President at the pharmaceutical company TaiGen. Formerly Director of the Medicinal Chemistry Department at the drug discovery and manufacturing company Albany Molecular Research Inc., sold to the Carlyle Group for $1.5bn in 2017.

Chihliang (“Andy”) An Chief Financial Officer

Previously Managing Director of the investment team at Yinyai Investment (Hong Kong). BSc, Statistics from Tamkang University in Taiwan; MBA in Finance, University of Kentucky.

NASDAQ: ABVC

Financial Highlights (as of September 30, 2021)

Paid-in Capital	$49,716,411
Cash (Not including exercise of Series A Warrants)	$4,449,772
Approximate Burn Rate	$500,000 per month
Shareholder Equity	$7,589,741
Shares Outstanding	27,935,783
Market Cap (as of September 30, 2021)	61,964,000



NASDAQ: ABVC

SPRING 2022

Growth Strategy 2022

- MDD Phase II clinical study demonstrated material improvement in both efficacy and safety over existing medications available. ABVC will be seeking a Phase III partner in 2022 to demonstrate statistical significance for our MDD results.
- Vitargus has clear advantages over existing devices available to surgeons and will start a self-funded pivotal trial phase in 2022. United States FDA PMA is targeted for 2024.
- Several of our development programs may begin to deliver additional marketing opportunities such as corneal storage media, dietary supplements derived from the Maitake mushroom and others.
- Additional funding expected in 2022 to support continued Phase II clinical trials for oncology and ADHD medicines and to add entirely new drugs to our pipeline.

NASDAQ: ABVC

Legal Notice

With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.